ducovest

BBIXF:OTC- (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.0001

Change

0.00 (0.00)%

Market Cap

USD 0.07B

Volume

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
ARGNF argenx SE

N/A

 USD 34.32B
UCBJY UCB SA ADR

N/A

 USD 33.77B
UCBJF UCB SA

N/A

 USD 33.01B
WXIBF WuXi Biologics

N/A

 USD 12.07B
WXXWY WuXi Biologics (Cayman) Inc

N/A

 USD 12.07B
GNMSF Genmab A/S

N/A

 USD 12.01B
IVBIY IVBIY

N/A

 USD 11.04B
AKESF Akeso, Inc.

N/A

 USD 9.60B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

 USD 9.28B
SBMFF Sino Biopharmaceutical Limited

N/A

 USD 8.94B

ETFs Containing BBIXF

QCLN:F First Trust Nasdaq Clean .. 7.41 % 0.00 %

N/A

 N/A
QCLN:XETRA First Trust Nasdaq Clean .. 7.41 % 0.00 %

N/A

 N/A
USTP:XETRA Ossiam US Steepener UCITS.. 6.50 % 0.00 %

N/A

 N/A
DRUP:F Lyxor Index Fund - Lyxor .. 1.83 % 0.00 %

N/A

 N/A
MIDF 1.54 % 0.00 %

N/A

 N/A
IXN iShares Global Tech ETF 0.00 % 0.46 %

N/A

 N/A
XSD SPDR® S&P Semiconductor .. 0.00 % 0.35 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -99.50% 3% F N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.50% 3% F N/A F
Trailing 12 Months  
Capital Gain -99.75% 5% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.75% 5% F 1% F
Trailing 5 Years  
Capital Gain -99.92% 15% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.92% 15% F 3% F
Average Annual (5 Year Horizon)  
Capital Gain 754.74% 90% A- 95% A
Dividend Return 754.74% 90% A- 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 3,026.49% 12% F 5% F
Risk Adjusted Return 24.94% 83% B 65% D
Market Capitalization 0.07B 72% C 55% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector